Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study

Andrea Necchi, Associate Professor at Vita-Salute San Raffaele University, shared on X:

“IDO1 inhibition was ineffective in urothelial carcinoma.

Pembrolizumab and epacadostat/placebo for cis-ineligible urothelial carcinoma:

ECHO-307/KEYNOTE-672 study, BMC Cancer, also negatively tested in neoadjuvant setting.”

Source: Andrea Necchi/X

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

Authors: Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar and Ronald de Wit.